Literature DB >> 24940805

Ofloxacin resistance in Mycobacterium tuberculosis is associated with efflux pump activity independent of resistance pattern and genotype.

Zhaogang Sun1, Yuhui Xu, Yong Sun, Yi Liu, Xuxia Zhang, Hairong Huang, Chuanyou Li.   

Abstract

Drug-resistance to ofloxacin (OFX) in Mycobacterium tuberculosis is due to missense mutations in gyrA and other factors, such as alterations in the activity of drug efflux pumps. In this study, we identified 8 extensively drug resistant tuberculosis (XDR-TB), 40 multidrug resistant TB (MDR-TB), 38 polydrug resistant TB (PDR-TB), and 16 single OFX-resistant TB from 102 clinical isolates. We tested the effect of three efflux inhibitors, reserpine, verapamil, and carbonyl cyanide m-chlorophenyl hydrazone (CCCP), on changes in the OFX minimum inhibitory concentration (MIC) using Resazurin microtitre assay. These three inhibitors changed the MICs from 2- to 32-fold, with CCCP having the strongest effect. A total of 55%, 74%, and 83% of the tested isolates had changes in MIC of more than two-fold by reserpine, verapamil, and CCCP, respectively. The inhibitors led to similar fold-changes of OFX MICs in the XDR, MDR, PDR, and single OFX-resistant isolates. For each inhibitor, a higher resistance to OFX was associated with the greater efflux pump activity. There were no significant differences in the effect of efflux pump inhibitors upon Beijing and non-Beijing M. tuberculosis genotypes. Taken together, these results indicate that the efflux pump activity was greater in the isolates higher resistant to OFX and had similar effects on isolates with different drug resistant pattern, and had similar effects on Beijing and non-Beijing genotypes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24940805     DOI: 10.1089/mdr.2013.0171

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  7 in total

1.  The Orphan Response Regulator Rv3143 Modulates the Activity of the NADH Dehydrogenase Complex (Nuo) in Mycobacterium tuberculosis via Protein-Protein Interactions.

Authors:  Renata Płocińska; Karolina Wasik; Przemysław Płociński; Ewelina Lechowicz; Magdalena Antczak; Ewelina Błaszczyk; Bożena Dziadek; Marcin Słomka; Anna Rumijowska-Galewicz; Jarosław Dziadek
Journal:  Front Cell Infect Microbiol       Date:  2022-06-28       Impact factor: 6.073

2.  Unique Physiological and Genetic Features of Ofloxacin-Resistant Streptomyces Mutants.

Authors:  Kanata Hoshino; Ryoko Hamauzu; Hiroyuki Nakagawa; Shinya Kodani; Takeshi Hosaka
Journal:  Appl Environ Microbiol       Date:  2021-12-22       Impact factor: 5.005

3.  A novel resistance mutation in eccC5 of the ESX-5 secretion system confers ofloxacin resistance in Mycobacterium tuberculosis.

Authors:  Brandon Eilertson; Fernanda Maruri; Amondrea Blackman; Yan Guo; Miguel Herrera; Yuri van der Heijden; Yu Shyr; Timothy R Sterling
Journal:  J Antimicrob Chemother       Date:  2016-06-03       Impact factor: 5.790

4.  Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis.

Authors:  Chao Chen; Susana Gardete; Robert Sander Jansen; Annanya Shetty; Thomas Dick; Kyu Y Rhee; Véronique Dartois
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

5.  Involvement of the RND efflux pump transporter SmeH in the acquisition of resistance to ceftazidime in Stenotrophomonas maltophilia.

Authors:  Paula Blanco; Fernando Corona; José Luis Martínez
Journal:  Sci Rep       Date:  2019-03-20       Impact factor: 4.379

Review 6.  Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes.

Authors:  Yuhui Xu; Jianan Wu; Sha Liao; Zhaogang Sun
Journal:  Ann Clin Microbiol Antimicrob       Date:  2017-10-03       Impact factor: 3.944

Review 7.  The Mycobacterial Membrane: A Novel Target Space for Anti-tubercular Drugs.

Authors:  Huan Chen; Samuel A Nyantakyi; Ming Li; Pooja Gopal; Dinah B Aziz; Tianming Yang; Wilfried Moreira; Martin Gengenbacher; Thomas Dick; Mei L Go
Journal:  Front Microbiol       Date:  2018-07-19       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.